Dr. Kumar, a globally recognized authority on clinical trials in India has been involved with over 200 clinical trials and 20 New Drug Application approvals in the USA, Europe and Asia. Excel Life Sciences’ service offerings include clinical trials, technology transfer, product licensing, formulation research, new product development, establishing GCP compliant sites and training of all clinical trials stakeholders, with an emphasis on emerging markets.
Los Angeles, CA (PRWEB) November 1, 2006 -- Excel Life Sciences , a U.S. based, India focused Life Sciences Company, announced today that it has hired Dr. Vijai Kumar to serve as the company's President and Chief Medical Officer, effective immediately. Dr. Kumar, a globally recognized authority on clinical trials in India has been involved with over 200 clinical trials and 20 New Drug Application approvals in the USA, Europe and Asia. Excel Life Sciences' service offerings include clinical trials, technology transfer, product licensing, formulation research, new product development, establishing GCP compliant sites and training of all clinical trials stakeholders, with an emphasis on emerging markets.
"Dr. Kumar's leadership, combined with the unique assets of Excel Life Sciences, will create an unmatched presence in this industry. It will help biopharmaceutical companies conduct global clinical trials in India with confidence, while complying with the highest regulatory and ethical requirements" said Bedi Singh, Excel Life Sciences Chairman and former CFO of Novartis Pharmaceuticals. "His extensive experience in almost all aspects of drug development and research methodology will help us consistently exceed our customer expectations."
"Dr. Kumar's thought leadership, scientific and regulatory knowledge and extensive network of contacts make him an invaluable asset in the clinical research enterprise," said Kenneth Getz, Founder Chairperson of the Center for Information and Study of Clinical Research Participation (CISCRP), Senior Fellow at the Center for Study of Drug Development, Tufts University, Boston and founder and CEO of industry publication, CenterWatch.
Dr. Kumar previously served as the Global Medical Director of Neeman Medical Intl. In addition, he has been active in a variety of expert groups convened by the Drugs Controller General (India) to develop GCP guidelines and review the existing Drugs and Cosmetics Act. He has been closely involved in over 200 clinical trials conducted in India to date and has been associated with the growth and evolution of clinical research in India for over 30 years.
According to Dr. S.K. Gupta, Director General and Dean of Institute of Clinical Research (India), "Dr. Kumar is one of India's most eminent and globally recognized clinical researchers. His leadership and contributions to the industry are significant."
"Excel Life Sciences possesses a unique combination of talent, commitment and global vision that will enable this company to accomplish more than anyone has believed is possible in India," said Dr. Kumar. "It is a great honor to join its leadership team to take Excel Life Sciences to new heights, while continuing to champion the Indian talent and cause."
About Excel Life Sciences:
Excel Life Sciences is a US based India focused company whose service offerings include clinical trials, technology transfer, product licensing, formulation research, product development, establishing GCP compliant sites and training of all clinical trials stakeholders. The team has a combined experience of over 55 years in clinical research and regulatory affairs , 225 successfully conducted clinical trials, 120 IND and 20 NDA approvals in the USA, Europe and Asia. Excel Life Sciences is a one stop solution for conducting FDA compliant trials with reduced screen failure, rapid recruitment and maximal patient retention. The Company's offerings allow multi-national biopharmaceutical companies to capitalize on the recent regulatory reforms in India to accelerate drug development.
For further information, please contact:
Mohit Mehrotra
773-251-2976
# # #
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1IYWxmLUhhbGYtQ291cC1NYWduLVplcm8=
|
